=== Intervention Extract 1 (Treatment) ===
of MRI compared to CCT in patients with brain metastases. J
Neurooncol. 1999;44(3):275-81.
2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic
patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003
Nov;42(2):189-93.
3 - Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of
changing imaging techniques (CT versus MRI). Cancer. 2008 Apr 15;112(8):1827-34
Uitgangsvraag
Wat zijn prognostische factoren bij patiën

=== Intervention Extract 2 (Treatment) ===
ProGRP prognostische waarde hebben.
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Referenties
1 - Gillenwater HH, Socinski MA. Extensive stage small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, Rosenman
JG, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician, 25, 2001. Pp 360-75.
Philadelphia: W.B. Saunders Company.
2 - Cerry T, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung
cancer patients. International Journal of Cancer

=== Intervention Extract 3 (Treatment) ===
I-II small-cell lung cancer. Am J Clin Oncol 1993; 16(2):93-95.
4 - de Antonio DG, Alfageme F, Gamez P, Cordoba M, Varela A: Results of surgery in small cell carcinoma of the lung. Lung
Cancer 2006; 52(3):299-304.
5 - Fujimori K, Yokoyama A, Kurita Y, Terashima M: A pilot phase 2 study of surgical treatment after induction chemotherapy
for resectable stage I to III A small cell lung cancer. Chest 1997; 111(4):1089-1093.
6 - Granetzny A, Boseila A, Wagner W, Krukemeyer G, Vogt U, Hecker E, Koch OM, Klinke F: Surgery in the tri-modality
treatment of small cell lung cancer. Stage-dependent survival. Eur

=== Intervention Extract 4 (Treatment) ===
Kurita Y, Terashima M: A pilot phase 2 study of surgical treatment after induction chemotherapy
for resectable stage I to III A small cell lung cancer. Chest 1997; 111(4):1089-1093.
6 - Granetzny A, Boseila A, Wagner W, Krukemeyer G, Vogt U, Hecker E, Koch OM, Klinke F: Surgery in the tri-modality
treatment of small cell lung cancer. Stage-dependent survival. Eur J Cardiothorac Surg 2006; 30(2):212-216.
7 - Hara N, Ichinose Y, Kuda T, Asoh H, Yano T, Kawasaki M, Ohta M: Long-term survivors in resected and nonresected small
cell lung cancer. Oncology 1991; 48(6):441-447. Harrison's Online > Part Six: O

=== Intervention Extract 5 (Treatment) ===
in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology
Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005; 129(5):977-983.
14 - Wada H, Yokomise H, Tanaka F, Hirata T, Fukuse T, Bando T, Inui K, Ike O, Mizuno H, Hitomi S: Surgical treatment of
small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer 1995; 13(1):45-56.
15 - Hanagiri T, Sugio K, Baba T, Ichiki Y, Yasuda M, Uramoto H, Ohga T, Takenoyama M, Yasumoto K: Results of surgical
treatment for patients with small cell lung cancer. J Thorac Oncol 2009;

=== Intervention Extract 6 (Treatment) ===
Fukuse T, Bando T, Inui K, Ike O, Mizuno H, Hitomi S: Surgical treatment of
small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer 1995; 13(1):45-56.
15 - Hanagiri T, Sugio K, Baba T, Ichiki Y, Yasuda M, Uramoto H, Ohga T, Takenoyama M, Yasumoto K: Results of surgical
treatment for patients with small cell lung cancer. J Thorac Oncol 2009; 4(8):964-968
Kleincellig longcarcinoom - Inductiechemotherapie gevolgd door chirurgie
Uitgangsvraag
Waaruit bestaat de behandeling van patiënten met limited disease kleincellig loncarcinoom?
Aanbeveling
Voor patiënten met stadium I-II S

=== Intervention Extract 7 (Treatment) ===
avaretto A, Loy M, Paccagnella A, Fantoni U, Festi G, Sartori F: Long term results of surgery and
chemotherapy in small cell lung cancer. Eur J Cardiothorac Surg 1998; 14(4):398-402.
2 - Granetzny A, Boseila A, Wagner W, Krukemeyer G, Vogt U, Hecker E, Koch OM, Klinke F: Surgery in the tri-modality
treatment of small cell lung cancer. Stage-dependent survival. Eur J Cardiothorac Surg 2006; 30(2):212-216.
3 - Nakamura H, Kato Y, Kato H: Outcome of surgery for small cell lung cancer -- response to induction chemotherapy predicts
survival. Thorac Cardiovasc Surg 2004; 52(4):206-210.
4 - Badzio A, Kurowski

=== Intervention Extract 8 (Treatment) ===
I-II small-cell lung cancer. Am J Clin Oncol 1993; 16(2):93-95.
7 - de Antonio DG, Alfageme F, Gamez P, Cordoba M, Varela A: Results of surgery in small cell carcinoma of the lung. Lung
Cancer 2006; 52(3):299-304.
8 - Fujimori K, Yokoyama A, Kurita Y, Terashima M: A pilot phase 2 study of surgical treatment after induction chemotherapy
for resectable stage I to III A small cell lung cancer. Chest 1997; 111(4):1089-1093.
9 - Hara N, Ichinose Y, Kuda T, Asoh H, Yano T, Kawasaki M, Ohta M: Long-term survivors in resected and nonresected small
cell lung cancer. Oncology 1991; 48(6):441-447. Harrison's Onl

=== Intervention Extract 9 (Treatment) ===
Yokomise H, Tanaka F, Hirata T, Fukuse T, Bando T, Inui K, Ike O, Mizuno H, Hitomi S: Surgic
small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer 1995; 13(1):45-56
15 - Hanagiri T, Sugio K, Baba T, Ichiki Y, Yasuda M, Uramoto H, Ohga T, Takenoyama M, Yasumoto K: Re
treatment for patients with small cell lung cancer. J Thorac Oncol 2009; 4(8):964-968
For the ISC-
ment of smal
apy for T1-3N
perative adjuv
Clinical Onco
cal treatmen
esults of surg
-Lung
ll cell
N0M0
vant
ology
nt of
gical
Kleincellig longcarcinoom - Systemische behandeling en radiother
Uitgangsvraag
Waaru

=== Intervention Extract 10 (Treatment) ===
tandig. Het wordt aanbevolen om als
orale dosis het dubbele van i.v. te geven.
B (27)
C (2) (4) (5)
D (28)
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Referenties
1 - Toffoli G, Corona G, Basso B, Boiocchi M. Pharmacokinetic optimisation of treatment with oral etoposide. Clin
Pharmacokinet 2004:47 (7);441-466
2 - Slevin ML, Joel SP, Whomsley R, rt al. The effect of dose on the bioavailability or oral etoposide: confirmation of a clinically
relevant observation. Cancer Chemother Pharmacol 1989; 24 (5) 329-31
Uitgangsvraag
Wat is de plaats van do

=== Intervention Extract 11 (Treatment) ===
compared to CCT in patients with brain metastases. J Neurooncol. 1999;44(3):275-81.
Row 6: 2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003 Nov;42(2):189-93.
Row 7: Nov;42(2):189-93.
Row 8: 3 - Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008 Apr 15;112(8):1827-34
Row 9: 4 - Bradley JD, D

=== Intervention Extract 12 (Treatment) ===
ige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 - Gillenwater HH, Socinski MA. Extensive stage small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician, 25, 2001. Pp 360-75. Philadelphia: W.B. Saunders Company.
Row 6: 2 - Cerry T, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. International Journal of

=== Intervention Extract 13 (Treatment) ===
l lung cancer. Am J Clin Oncol 1993; 16(2):93-95.
Row 9: 4 - de Antonio DG, Alfageme F, Gamez P, Cordoba M, Varela A: Results of surgery in small cell carcinoma of the lung. Lung Cancer 2006; 52(3):299-304.
Row 10: 5 - Fujimori K, Yokoyama A, Kurita Y, Terashima M: A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to III A small cell lung cancer. Chest 1997; 111(4):1089-1093.
Row 11: 6 - Granetzny A, Boseila A, Wagner W, Krukemeyer G, Vogt U, Hecker E, Koch OM, Klinke F: Surgery in the tri-modality
Row 12: 
Row 13: PDF aangemaakt op 23-01-2025 31/148
Row 14

=== Intervention Extract 14 (Treatment) ===
ng cancer. Chest 1997; 111(4):1089-1093.
Row 11: 6 - Granetzny A, Boseila A, Wagner W, Krukemeyer G, Vogt U, Hecker E, Koch OM, Klinke F: Surgery in the tri-modality
Row 12: 
Row 13: PDF aangemaakt op 23-01-2025 31/148
Row 14:  Row 1: ||
Row 2: ||
Row 3: Kleincellig longcarcinoom||
Row 4: ||
Row 5: treatment of small cell lung cancer. Stage-dependent survival.|Eur J Cardiothorac Surg 2006; 30(2):212-216.|
Row 6: 7|| Row 1: 
Row 2: PDF aangemaakt op 23-01-2025 32/148 Row 1: Kleincellig longcarcinoom
Row 2: Kleincellig longcarcinoom - Inductiechemotherapie gevolgd door chirurgie
Row 3: 
Row 4: Uitgangsvr

=== Intervention Extract 15 (Treatment) ===
die was de incidentie van graad III oesofagitis 18%, wat precies overeenkomt met de incidentie in de CONVERT-studie.||
Row 22: ||
Row 23: In de studie van Faivre-Finn (2017) kon bij tweemaal daagse radiotherapie 98% van de patiënten de gewenste dosis van 45 Gy krijgen en 20% had een langere overall treatment time dan 21 dagen, terwijl in de eenmaal daagse groep 83% de vooropgestelde dosis van 66 Gy kreeg en 18% een verlenging van de behandelduur van boven 49 dagen. 78% van de patiënten in de tweemaal daagse groep en 65% in de eenmaal daagse groep kreeg dus een bestralingsdosis en -intensiteit die optim

=== Intervention Extract 16 (Treatment) ===
011
Row 9: Laatst geautoriseerd|: 10-05-2011 Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 Row 1: 162-9.|||
Row 2: 2|- Brahmer JR, Ettinger DS (1998). "Carboplatin in the Treatment of Small Cell Lung Cancer."|Oncologist 3(3): 143-154|.
Row 3: 3||| Row 1: 4
Row 2: Cochrane Database Syst Rev(4): CD006849
Row 3: 
Row 4: PDF aangemaakt op 23-01-2025 61/148 Row 1: Kleincellig longcarcinoom
Row 2: Kleincellig longcarcinoom - Toevoegen 2de chemotherapeuticum
Row 3: 
Row 4: Uitgangsv

=== Intervention Extract 17 (Treatment) ===
G, et al. (2002). "Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer." J Clin Oncol 20(22): 4434-9.
Row 6: 4434-9.
Row 7: 2 - Pujol JL, Breton JL, et al. (2007). "Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small
Row 8: PDF aangemaakt op 23-01-2025 69/148
Row 9: 
Row 10:  Row 1: 
Row 2: 
Row 3: Kleincellig longcarci

=== Intervention Extract 18 (Treatment) ===
Clin Oncol 1987; 23(11):1697-1699.|Eur J Cancer Clin Oncol 1987;||
Row 7: 3 - Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988; 21(1):45-48.|||Cancer Chemother
Row 8: 4 - Collard P, Weynants P, Francis C et al. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin. Thorax 1992; 47(5):369-371.|||
Row 9: 5 - Batist G, Ihde DC, Zabell A et al. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern M

=== Intervention Extract 19 (Treatment) ===
1 Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.|
Row 2: |
Row 3: Referenties|
Row 4: |
Row 5: 1 - von Pawel J, Schiller JH, Shepherd FA et al. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer. J Clin Oncol 1999; 17(2):658-667.|
Row 6: 2 - Sculier JP, Lafitte JJ, Lecomte J et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol

=== Intervention Extract 20 (Treatment) ===
second-line therapy for small-cell lung cancer. Ann Oncol 2002; 13(9):1454-1459.|
Row 7: |Ann Oncol 2002; 13(9):1454-1459.
Row 8: 3 - O'Bryan RM, Crowley JJ, Kim PN et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer 1990; 65(4):856-860.|
Row 9: 1990; 65(4):856-860.|
Row 10: 4 - Agelaki S, Syrigos K, Christophylakis C et al. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-c

=== Intervention Extract 21 (Treatment) ===
29-333.|
Row 12: 6 - Ando M, Kobayashi K, Yoshimura A et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004; 44(1):121-127.|
Row 13: 7 - Ardizzoni A, Manegold C, Debruyne C et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer. Clin Cancer Res 2003; 9(1):143-150.|
Row 14: 8 - Castellano DE, Ciruelos E, Garcia-Giron C et al. Phase II trial of biweekly irinotecan plus

=== Intervention Extract 22 (Treatment) ===
lus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004; 44(1):121-127.|
Row 13: 7 - Ardizzoni A, Manegold C, Debruyne C et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer. Clin Cancer Res 2003; 9(1):143-150.|
Row 14: 8 - Castellano DE, Ciruelos E, Garcia-Giron C et al. Phase II trial of biweekly irinotecan plus gemcitabine combination in refractory or relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Cl

=== Intervention Extract 23 (Treatment) ===
elos E, Garcia-Giron C et al. Phase II trial of biweekly irinotecan plus gemcitabine combination in refractory or relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 2003; 21:2710.|
Row 15: 9 - Choi HJ, Cho BC, Shin SJ et al. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemother Pharmacol 2008; 61(2):309-313.|
Row 16: 61(2):309-313|
Row 17: 10 - Christodoulou C, Kalofonos HP, Briasoulis E et al. Combination of topotecan and cisplatin in relapsed pa

=== Intervention Extract 24 (Treatment) ===
zalea Larriba JL, Garcia Gomez R et al. CPT-11-gemcitabine for refractory or relapsed small cell lung cancer (SCLC). A Spanish multicentric phase II study [abstract]. Proc Am Soc Clin Oncol 2003; 22:2819.|
Row 20: 12 - Domine M, Larriba JL, Morales S et al. Gemcitabine and paclitaxel as second line treatment in small cell lung cancer (SCLC) A multicentric phase II study. [abstract]. Proc Am Soc Clin Oncol 2001; 20.|
Row 21: 13 - Dongiovanni V, Buffoni L, Berruti A et al. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and

=== Intervention Extract 25 (Treatment) ===
-209.|
Row 23: 14 - Dudek AZ, Lesniewski-Kmak K, Bliss RL et al. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung 2005; 183(1):43-52.|
Row 24: 15 - Evans WK, Osoba D, Feld R et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985; 3(1):65-71.|
Row 25: PDF aangemaakt op 23-01-2025 99/148|
Row 26: | Row 1: 
Row 2: 
Row 3: 
Row 4: Kleincellig longcarcinoom
Row 5: 1 Row 1: 52(3):327-332.
Row 2: 2 Row 1: Cancer 1993; 29A(2):204-207.
Row 2: 3 Row 1: Clin Oncol 2006; 24(33):

=== Intervention Extract 26 (Treatment) ===
of anorexia-cachexia.|Clin Opin Oncol 1999;11:255-260|
Row 2: 6||| Row 1: Clin oncol 1993;11:2043-9.
Row 2: 7 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:27.||
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.|||
Row 3: 1||||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–68.||||||
R

=== Intervention Extract 27 (Treatment) ===
ugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–68.||||||
Row 3: 1|5 - Argiles JM, Meijsing SH, Pallares-Trujillo J, et al. Cancer cachexia: A therapeutic approach.|||||Med Res Rev 2001;21:83–101.||
Row 4: 1|6 - Bruera E. Pharmacological treatment of cachexia: Any progress?||Support Care Cancer 1998;6:109–113||||.|
Row 5: 1|||||||| Row 1: Clin Oncol 1996;14:135–141.
Row 2: 2 Row 1: 
Row 2: PDF aangemaakt op 23-01-2025 120/148
Row 3:  Row 1: 
Row 2: Kleincellig longcarcinoom
Row 3: Voor de volledige verantwoording, evidence tabellen en eventu

=== Intervention Extract 28 (Treatment) ===
era E. Anorexia, cachexia and nutrition.|B Med J 1997;315:1219-1222|.|
Row 2: 4||||Curr Clin Nutr Metab Care 1999 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:2|
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.||
Row 3: 1|||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–68.||||||
Row

=== Intervention Extract 29 (Treatment) ===
||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–68.||||||
Row 3: 1|5 - Argiles JM, Meijsing SH, Pallares-Trujillo J, et al. Cancer cachexia: A therapeutic approach.|||||Med Res Rev 2001;21:8||
Row 4: 1|6 - Bruera E. Pharmacological treatment of cachexia: Any progress?||Support Care Cancer 1998;6:109–113||||.|
Row 5: 1|||||||| Row 1: 
Row 2: PDF aangemaakt op 23-01-2025 1 Row 1: |
Row 2: |
Row 3: u de|
Row 4: |
Row 5: |
Row 6: |
Row 7: With :5401-|
Row 8: nsights|
Row 9: |
Row 10: 9;2:339-|
Row 11: |
Row 12: |
Row 13: ight, y. J|
Row 14

=== Intervention Extract 30 (Drug) ===
drome of anorexia-cachexia.|Clin Opin Oncol 1999;11:255-260|
Row 2: 6||| Row 1: Clin oncol 1993;11:2043-9.
Row 2: 7 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:27.||
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.|||
Row 3: 1||||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–6

=== Intervention Extract 31 (Drug) ===
- Bruera E. Anorexia, cachexia and nutrition.|B Med J 1997;315:1219-1222|.|
Row 2: 4||||Curr Clin Nutr Metab Care 1999 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:2|
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.||
Row 3: 1|||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||
Row 2: 1|4 - Nelson KA. The cancer anorexia-cachexia syndrome.|Semin Oncol 2000;27:64–68.

=== Intervention Extract 32 (Therapy) ===
Lamy PJ, Grenier J, Kramar A, Pujol JL. Pro-gastrin-releasing peptide, neuron specific enolase and chrom
serum markers of small cell lung cancer. Lung Cancer 2000 September;29(3):197-203.
2 - Ebert W, Muley T, Trainer C, Dienemann H, Drings P. Comparison of changes in the NSE levels with clinic
the therapy monitoring of patients with SCLC. Anticancer Res 2002 March;22(2B):1083-9.
3 - Molina R. ProGRP: A New Biomarker for Small Cell Lung Cancer. Eur J Clin Med Oncol 2010 February;2
4 - Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K. Pro-gastrin-re
(ProGRP)--a usef

=== Intervention Extract 33 (Therapy) ===
slechte performance status
geeft overigens een beter resultaat dan behandeling met etoposide per os (9). Een studie uit 2008 toonde
aan dat high dose ifosfamide/cisplatin/etoposide geen overlevingsvoordeel oplevert ten opzichte van de
standaard dosering van deze cytostatica (10) (11)]. "Maintenance therapy" met cytostatica levert geen
meerwaarde op in termen van langere overleving (12) (13) (14) (15). Tot nu toe tonen ook de "targeted
therapies" geen voordeel bij de behandeling van SCLC (zoals bv de metallo-proteinasen, C-Kit rec.,EGFR
antagonisten, angiogenese remmers, anti Bcl 2 inhibitoren, vaccin

=== Intervention Extract 34 (Therapy) ===
rathyroid hormone. Endocr Pract. 2003 Jan-
Feb;9(1)
7 - Stuart-Harris R, Ahern V, Danks JA, Gurney H, Martin TJ. Hypercalcaemia in small cell lung cancer: report of a case
associated with parathyroid hormone-related protein (PTHrP) Eur J Cancer. 1993;29A(11):1601-4
8 - Dainer PM. Octreotide acetate therapy for hypercalcemia complicating small cell carcinoma of the lung. South Med J. 1991
Oct;84(10):1250-4. (Comment in:South Med J. 1992 May;85(5):561)
9 - Hayward ML Jr, Howell DA, O'Donnell JF, Maurer LH. Hypercalcemia complicating small-cell carcinoma. Cancer. 1981 Oct
1;48(7):1643-6 ref PMB/HPAO
10

=== Intervention Extract 35 (Therapy) ===
slechte performance status geeft overigens een beter resultaat dan behandeling met etoposide per os (9). Een studie uit 2008 toonde aan dat high dose ifosfamide/cisplatin/etoposide geen overlevingsvoordeel oplevert ten opzichte van de standaard dosering van deze cytostatica (10) (11)]. "Maintenance therapy" met cytostatica levert geen meerwaarde op in termen van langere overleving (12) (13) (14) (15). Tot nu toe tonen ook de "targeted therapies" geen voordeel bij de behandeling van SCLC (zoals bv de metallo-proteinasen, C-Kit rec.,EGFR antagonisten, angiogenese remmers, anti Bcl 2 inhibitoren, vaccin

=== Intervention Extract 36 (Therapy) ===
% en boven 60 Gy 53-96%. Deze resultaten moeten echter voorzichtig geïnterpreteerd worden, omdat de studies sterk varieerden met betrekking tot het bestraalde volume, de behandeltijd en het type en de sequentie van de chemotherapie.
Row 12: In een fase I studie die werd uitgevoerd door de Radiation Therapy Oncology Group (RTOG 97-12) bedroeg de maximaal tolereerbare bestralingsdosis 61,2 Gy in 5 weken, wanneer dit tegelijk werd toegediend met cisplatin-etoposide (2). Verschillende fase III studies hebben de timing (vroege vs late thoracale bestraling) en de volgorde van bestraling en chemotherapie (s

=== Intervention Extract 37 (Therapy) ===
, Weynants P, Francis C et al. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin. Thorax 1992; 47(5):369-371.|||
Row 9: 5 - Batist G, Ihde DC, Zabell A et al. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern Med 1983 98(4):472-474.||Ann Intern Med 1983|
Row 10: |||
Row 11: PDF aangemaakt op 23-01-2025 91/148||| Row 1: Kleincellig longcarcinoom
Row 2: Kleincellig longcarcinoom - Monotherapie
Row 3: 
Row 4: Uitgangsvraag
Row 5: 
Row 6: Wat is de plaats van monotherapie bij

=== Intervention Extract 38 (Therapy) ===
oxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer. J Clin Oncol 1999; 17(2):658-667.|
Row 6: 2 - Sculier JP, Lafitte JJ, Lecomte J et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002; 13(9):1454-1459.|
Row 7: |Ann Oncol 2002; 13(9):1454-1459.
Row 8: 3 - O'Bryan RM, Crowley JJ, Kim PN et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small

=== Intervention Extract 39 (Dose) ===
, paclitaxel en ifosfamide tonen geen extra voordeel ten opzichte van etoposide,
gecombineerd met cisplatin. Combinatie chemotherapie in patiënten met een slechte performance status
geeft overigens een beter resultaat dan behandeling met etoposide per os (9). Een studie uit 2008 toonde
aan dat high dose ifosfamide/cisplatin/etoposide geen overlevingsvoordeel oplevert ten opzichte van de
standaard dosering van deze cytostatica (10) (11)]. "Maintenance therapy" met cytostatica levert geen
meerwaarde op in termen van langere overleving (12) (13) (14) (15). Tot nu toe tonen ook de "targeted
therapies"

=== Intervention Extract 40 (Dose) ===
rantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Referenties
1 - Toffoli G, Corona G, Basso B, Boiocchi M. Pharmacokinetic optimisation of treatment with oral etoposide. Clin
Pharmacokinet 2004:47 (7);441-466
2 - Slevin ML, Joel SP, Whomsley R, rt al. The effect of dose on the bioavailability or oral etoposide: confirmation of a clinically
relevant observation. Cancer Chemother Pharmacol 1989; 24 (5) 329-31
Uitgangsvraag
Wat is de plaats van dosisintensificatie bij behandeling van patiënten met extensive disease kleincellig
longcarcinoom?
Aanbeveling
Er is geen pl

=== Intervention Extract 41 (Dose) ===
, paclitaxel en ifosfamide tonen geen extra voordeel ten opzichte van etoposide, gecombineerd met cisplatin. Combinatie chemotherapie in patiënten met een slechte performance status geeft overigens een beter resultaat dan behandeling met etoposide per os (9). Een studie uit 2008 toonde aan dat high dose ifosfamide/cisplatin/etoposide geen overlevingsvoordeel oplevert ten opzichte van de standaard dosering van deze cytostatica (10) (11)]. "Maintenance therapy" met cytostatica levert geen meerwaarde op in termen van langere overleving (12) (13) (14) (15). Tot nu toe tonen ook de "targeted therapies"

=== Intervention Extract 42 (Dose) ===
0-05-2011
Row 10: Laatst geautoriseerd|: 10-05-2011 Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 Row 1: 3|- Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide.|J Clin Oncol 1993; 11 (2) 374-7|
Row 2: 4||| Row 1: 9|- Arnold AM, Whitehouse JM. Etoposide: a new anti-cancer agent.|Lancet 1981: II (8252) 912-5|
Row 2: 1||| Row 1: 1|7 - Taal BG, Beijnen JH, Teller FG, et al. Bioavailability of oral etoposide in gastric cancer.|Eur J cancer 1994:

